Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748115 | 0.86 | SMYD2 (0.39) | SMYD2CYP3A4SMN1; SMN2HTT | |
| SCHEMBL25364479 | 0.84 | RIPK1 (0.42) | SMYD2CYP3A4SMN1; SMN2HTTRIPK1 | |
| SCHEMBL18587707 | 0.84 | RIPK1 (0.42) | SMYD2CYP3A4SMN1; SMN2HTTRIPK1 | |
| SCHEMBL25365732 | 0.84 | RIPK1 (0.42) | SMYD2CYP3A4SMN1; SMN2HTTRIPK1 | |
| SCHEMBL2146189 | 0.84 | RIPK1 (0.42) | SMYD2CYP3A4SMN1; SMN2HTTRIPK1 | |
| SCHEMBL7328073 | 0.83 | MAPT (0.40) | SMYD2MGAM | |
| SCHEMBL10417697 | 0.83 | MAPT (0.40) | SMYD2MGAM | |
| SCHEMBL5152621 | 0.80 | CYP1A2 (0.41) | SMYD2CYP3A4RIPK1 | |
| SCHEMBL5150301 | 0.80 | CYP1A2 (0.41) | SMYD2CYP3A4RIPK1 | |
| SCHEMBL28396275 | 0.80 | CYP1A2 (0.41) | SMYD2CYP3A4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | PHAX, RIOX2, RNMT | SMYD2 2771/4885CYP3A4 4498/4885SMN1; SMN2 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.